Vaccine

Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.

Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE)…

2 years ago

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

CHATHAM, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage…

2 years ago

CancerVAX CEO Ryan Davies Discusses the Company’s Growing Pipeline of Cancer Treatments

The Company’s development pipeline now includes three projects with UCLALEHI, Utah, Sept. 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a…

2 years ago

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership…

2 years ago

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic…

2 years ago

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers…

2 years ago

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)ALBANY, N.Y., Sept. 13,…

2 years ago

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE…

2 years ago

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests…

2 years ago

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…

2 years ago